Figure 5

Figure 5

Tacrine, but not duloxetine, promotes restoration of locomotor activity. (a) Representative tracking image of a 5-min recording at 8 dpf. Quantification of (b) total distance moved (control: 1476.41 ± 975.90, MTZ: 539.10 ± 369.30, recovery: 655.05 ± 441.90, 250 nM tacrine: 1093.44 ± 670.50, 10 μM duloxetine: 243.87 ± 383.45), (c) velocity (control: 1.64 ± 1.09, MTZ: 0.60 ± 0.41, recovery: 0.73 ± 0.49, 250 nM tacrine: 1.19 ± 0.75, 10 μM duloxetine: 0.27 ± 0.42), (d) total movement time (control: 327.08 ± 200.34, MTZ: 120.81 ± 90.72, recovery: 148.80 ± 109.57, 250 nM tacrine: 252.45 ± 176.18, 10 μM duloxetine: 50.55 ± 113.43), and (e) total resting time (control: 572.91 ± 200.34, MTZ: 779.18 ± 90.72, recovery: 751.19 ± 109.57, 250 nM tacrine: 647.54 ± 176.18, 10 μM duloxetine: 549.44 ± 113.43) during 15-min recordings. The experiment was independently repeated three times (n = 31 per group). Error bars indicate mean ± standard deviation. ***p < 0.001; **p < 0.01; *p < 0.05; n.s., not significant.